Advanced

A systematic analysis of commonly used antibodies in cancer diagnostics

Gremel, Gabriela; Bergman, Julia; Djureinovic, Dijana; Edqvist, Per-Henrik; Maindad, Vikas; Bharambe, Bhavana M.; Khan, Wasif Ali Z. A.; Navani, Sanjay; Elebro, Jacob LU and Jirström, Karin LU , et al. (2014) In Histopathology 64(2). p.293-305
Abstract
AimsImmunohistochemistry plays a pivotal role in cancer differential diagnostics. To identify the primary tumour from a metastasis specimen remains a significant challenge, despite the availability of an increasing number of antibodies. The aim of the present study was to provide evidence-based data on the diagnostic power of antibodies used frequently for clinical differential diagnostics. Methods and resultsA tissue microarray cohort comprising 940 tumour samples, of which 502 were metastatic lesions, representing tumours from 18 different organs and four non-localized cancer types, was analysed using immunohistochemistry with 27 well-established antibodies used in clinical differential diagnostics. Few antibodies, e.g. prostate-specific... (More)
AimsImmunohistochemistry plays a pivotal role in cancer differential diagnostics. To identify the primary tumour from a metastasis specimen remains a significant challenge, despite the availability of an increasing number of antibodies. The aim of the present study was to provide evidence-based data on the diagnostic power of antibodies used frequently for clinical differential diagnostics. Methods and resultsA tissue microarray cohort comprising 940 tumour samples, of which 502 were metastatic lesions, representing tumours from 18 different organs and four non-localized cancer types, was analysed using immunohistochemistry with 27 well-established antibodies used in clinical differential diagnostics. Few antibodies, e.g. prostate-specific antigen and thyroglobulin, showed a cancer type-related sensitivity and specificity of more than 95%. A majority of the antibodies showed a low degree of sensitivity and specificity for defined cancer types. Combinations of antibodies provided limited added value for differential diagnostics of cancer types. ConclusionsThe results from analysing 27 diagnostic antibodies on consecutive sections of 940 defined tumours provide a unique repository of data that can empower a more optimal use of clinical immunohistochemistry. Our results highlight the benefit of immunohistochemistry and the unmet need for novel markers to improve differential diagnostics of cancer. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biological tumour markers, differential diagnosis, immunohistochemistry, surgical pathology, tissue microarray analysis
in
Histopathology
volume
64
issue
2
pages
293 - 305
publisher
Wiley-Blackwell
external identifiers
  • wos:000328347800012
  • scopus:84890154421
ISSN
0309-0167
DOI
10.1111/his.12255
language
English
LU publication?
yes
id
c22c0aa2-8c37-45ee-a995-5a8388bcff0d (old id 4261893)
date added to LUP
2014-02-10 12:16:28
date last changed
2017-03-26 03:15:10
@article{c22c0aa2-8c37-45ee-a995-5a8388bcff0d,
  abstract     = {AimsImmunohistochemistry plays a pivotal role in cancer differential diagnostics. To identify the primary tumour from a metastasis specimen remains a significant challenge, despite the availability of an increasing number of antibodies. The aim of the present study was to provide evidence-based data on the diagnostic power of antibodies used frequently for clinical differential diagnostics. Methods and resultsA tissue microarray cohort comprising 940 tumour samples, of which 502 were metastatic lesions, representing tumours from 18 different organs and four non-localized cancer types, was analysed using immunohistochemistry with 27 well-established antibodies used in clinical differential diagnostics. Few antibodies, e.g. prostate-specific antigen and thyroglobulin, showed a cancer type-related sensitivity and specificity of more than 95%. A majority of the antibodies showed a low degree of sensitivity and specificity for defined cancer types. Combinations of antibodies provided limited added value for differential diagnostics of cancer types. ConclusionsThe results from analysing 27 diagnostic antibodies on consecutive sections of 940 defined tumours provide a unique repository of data that can empower a more optimal use of clinical immunohistochemistry. Our results highlight the benefit of immunohistochemistry and the unmet need for novel markers to improve differential diagnostics of cancer.},
  author       = {Gremel, Gabriela and Bergman, Julia and Djureinovic, Dijana and Edqvist, Per-Henrik and Maindad, Vikas and Bharambe, Bhavana M. and Khan, Wasif Ali Z. A. and Navani, Sanjay and Elebro, Jacob and Jirström, Karin and Hellberg, Dan and Uhlen, Mathias and Micke, Patrick and Ponten, Fredrik},
  issn         = {0309-0167},
  keyword      = {biological tumour markers,differential diagnosis,immunohistochemistry,surgical pathology,tissue microarray analysis},
  language     = {eng},
  number       = {2},
  pages        = {293--305},
  publisher    = {Wiley-Blackwell},
  series       = {Histopathology},
  title        = {A systematic analysis of commonly used antibodies in cancer diagnostics},
  url          = {http://dx.doi.org/10.1111/his.12255},
  volume       = {64},
  year         = {2014},
}